Sight Sciences (NASDAQ:SGHT) is a medical device company focused on developing innovative products that address unmet needs in the treatment of eye diseases and conditions. Their portfolio mainly revolves around technologies aimed at improving the outcomes of patients suffering from glaucoma and dry eye disease. By investing in research and development, Sight Sciences aims to push the boundaries of ophthalmology and optometry, introducing solutions that can significantly improve quality of life. Their mission is to provide cutting-edge treatments that offer more effective and safer alternatives to traditional surgical procedures. As a single-listed entity, Sight Sciences leverages its position on NASDAQ:SGHT to further its research endeavors, expand its market reach, and continue its commitment to advancing ocular health worldwide through innovation and collaboration.